The C-MIC device uses a constant electrical microcurrent to improve heart tissue inflammation and reduce edema. Credit: ramcreations/Shutterstock.

Berlin Heals secured €10m ($10.72m) in funding for CE approval of C-MIC, an implantable electroceutical device.

The company plans to use the funding to ensure the financial means for CE approval and paving the way for US market entry.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The device is designed to propagate reverse remodelling of the cardiac muscle tissue by providing a constant but minimal electrical direct current that is equivalent to physiological electrical currents in the heart.

Developed for patients with dilated cardiomyopathy, the C-MIC device, a life-saving technology, utilises a constant electrical microcurrent to improve heart tissue inflammation and reduce edema.

This patented technology has demonstrated clinical improvements in heart failure patients.

See Also:

Following the success of a pilot study involving ten patients, a further 35 C-MICs have been implanted in a randomised study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the recent funding, Berlin Heals is set to initiate studies in the US, with the Food and Drug Administration showing particular support for the device’s potential.

Berlin Heals anticipates CE certification for the device by late 2025 or early 2026.

Patients from the initial pilot study have been monitored for three years, maintaining NYHA class 1 status, performing well in the six-minute walk test and reporting a high sense of well-being.  

To date, around €40m has been invested in developing the C-MIC technology, the implant itself and market approval processes.

Berlin Heals CEO Marko Bagaric said: “We are convinced that we have developed a product for the treatment of severe heart failure that will restore quality of life to many patients worldwide and significantly extend their life expectancy.

“I am convinced that C-MIC will set a new standard in the treatment of these patients in the future. After a short operation, an imperceptible, constant microcurrent flows, which ensures that patients feel very well again within a few weeks.”